Zim Laboratories Limited (ZIMLAB) - Total Assets
Based on the latest financial reports, Zim Laboratories Limited (ZIMLAB) holds total assets worth Rs4.70 Billion INR (≈ $50.84 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Zim Laboratories Limited debt service capacity to assess how comfortably operating cash covers total debt obligations.
Zim Laboratories Limited - Total Assets Trend (2013–2025)
This chart illustrates how Zim Laboratories Limited's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Zim Laboratories Limited for net asset value and shareholders' equity analysis.
Zim Laboratories Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Zim Laboratories Limited's total assets of Rs4.70 Billion consist of 49.0% current assets and 51.0% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.4% |
| Accounts Receivable | Rs1.07 Billion | 22.7% |
| Inventory | Rs864.70 Million | 18.3% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs321.74 Million | 6.8% |
| Goodwill | Rs1.69 Million | 0.0% |
Asset Composition Trend (2013–2025)
This chart illustrates how Zim Laboratories Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ZIMLAB company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Zim Laboratories Limited's current assets represent 49.0% of total assets in 2025, a decrease from 68.0% in 2013.
- Cash Position: Cash and equivalents constituted 0.4% of total assets in 2025, down from 11.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 22.7% of total assets.
Zim Laboratories Limited Competitors by Total Assets
Key competitors of Zim Laboratories Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Beijing Sun Novo Pharmaceutical Research Co Ltd
SHG:688621
|
China | CN¥2.30 Billion |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
China | CN¥8.59 Billion |
|
Guangdong Lifestrong Pharmacy Co. Ltd.
SHE:301111
|
China | CN¥925.41 Million |
|
Jw Pharmac
KO:001060
|
Korea | ₩605.27 Billion |
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Samjin Pharm
KO:005500
|
Korea | ₩449.14 Billion |
Zim Laboratories Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.42 | 1.47 | 1.30 |
| Quick Ratio | 0.82 | 0.95 | 0.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs665.63 Million | Rs610.69 Million | Rs441.16 Million |
Zim Laboratories Limited - Advanced Valuation Insights
This section examines the relationship between Zim Laboratories Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 5.6% |
| Total Assets | Rs4.72 Billion |
| Market Capitalization | $58.62 Million USD |
Valuation Analysis
Below Book Valuation: The market values Zim Laboratories Limited's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Zim Laboratories Limited's assets grew by 5.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Zim Laboratories Limited (2013–2025)
The table below shows the annual total assets of Zim Laboratories Limited from 2013 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs4.72 Billion ≈ $51.05 Million |
+5.64% |
| 2024-03-31 | Rs4.47 Billion ≈ $48.32 Million |
+30.81% |
| 2023-03-31 | Rs3.42 Billion ≈ $36.94 Million |
-0.01% |
| 2022-03-31 | Rs3.42 Billion ≈ $36.95 Million |
+5.19% |
| 2021-03-31 | Rs3.25 Billion ≈ $35.12 Million |
-0.16% |
| 2020-03-31 | Rs3.25 Billion ≈ $35.18 Million |
-0.96% |
| 2019-03-31 | Rs3.28 Billion ≈ $35.52 Million |
+10.11% |
| 2018-03-31 | Rs2.98 Billion ≈ $32.26 Million |
+15.14% |
| 2017-03-31 | Rs2.59 Billion ≈ $28.02 Million |
+1.14% |
| 2016-03-31 | Rs2.56 Billion ≈ $27.70 Million |
-3.38% |
| 2015-03-31 | Rs2.65 Billion ≈ $28.67 Million |
+0.58% |
| 2014-03-31 | Rs2.64 Billion ≈ $28.51 Million |
+20.74% |
| 2013-03-31 | Rs2.18 Billion ≈ $23.61 Million |
-- |
About Zim Laboratories Limited
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. It provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. The company offers the… Read more